Repaglinide

Modify Date: 2024-01-02 07:11:51

Repaglinide Structure
Repaglinide structure
Common Name Repaglinide
CAS Number 135062-02-1 Molecular Weight 452.586
Density 1.1±0.1 g/cm3 Boiling Point 672.9±55.0 °C at 760 mmHg
Molecular Formula C27H36N2O4 Melting Point 129-130.2 °C
MSDS Chinese USA Flash Point 360.8±31.5 °C

 Use of Repaglinide


Repaglinide(AG-EE 623ZW) is a carbamoylmethyl benzoic acid (CMBA) derivative, which recently has become available for the treatment of type II diabetes. IC50 value:Target: Repaglinide is very rapidly absorbed (tmax less than 1 hour) with a t1/2 of less than one hour. Furthermore, repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) was effective (P < 0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes.

 Names

Name Repaglinide
Synonym More Synonyms

 Repaglinide Biological Activity

Description Repaglinide(AG-EE 623ZW) is a carbamoylmethyl benzoic acid (CMBA) derivative, which recently has become available for the treatment of type II diabetes. IC50 value:Target: Repaglinide is very rapidly absorbed (tmax less than 1 hour) with a t1/2 of less than one hour. Furthermore, repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) was effective (P < 0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes.
Related Catalog
References

[1]. Marbury T, Huang WC, Strange P, Lebovitz H et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Research and Clinical Practice .1999, 43(3):155-166.

[2]. David R. Owens . Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs . Diabetic Medicine 1998,15 : S28-S36.

[3]. J Fuhlendorff, P Rorsman, H Kofod. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 1998. 47 (3): 345-351 .

[4]. R Moses, R Slobodniuk, S Boyages. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care . 22 (1 ) : 119-124 .

[5]. Julio Rosenstock, MD, David R. Hassman, DO, Robert D. Madder, DO. Diabetes Care June 2004 vol. 27 no. 6 1265-1270

[6]. Shiling Hu1, Shuya Wang1, Barbara Fanelli1. Pancreatic β-Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide . JPET , 2000,293 (2 ): 444-452 .

 Chemical & Physical Properties

Density 1.1±0.1 g/cm3
Boiling Point 672.9±55.0 °C at 760 mmHg
Melting Point 129-130.2 °C
Molecular Formula C27H36N2O4
Molecular Weight 452.586
Flash Point 360.8±31.5 °C
Exact Mass 452.267517
PSA 78.87000
LogP 4.69
Vapour Pressure 0.0±2.2 mmHg at 25°C
Index of Refraction 1.568
Storage condition 2-8°C
Water Solubility DMSO: 34 mg/mL

 Safety Information

Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes Xn
RIDADR NONH for all modes of transport
WGK Germany 2
RTECS 000000033825
HS Code 2933399090

 Synthetic Route

 Customs

HS Code 2933399090
Summary 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Articles46

More Articles
[symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?

Drug Ther. Bull. 41(7) , 52-4, (2003)

[symbol: see text] Nateglinide (Starlix-Novartis) and [symbol: see text] repaglinide (NovoNorm-Novo Nordisk) are two of a new class of orally active antidiabetic drugs, the meglitinides. They have a r...

Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.

Clin. Pharmacokinet. 46(2) , 93-108, (2007)

This review describes the current knowledge on drug-drug and food-drug interactions with repaglinide and nateglinide. These two meglitinide derivatives, commonly called glinides, have been developed f...

Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.

Drug Metab. Dispos. 41(2) , 362-71, (2013)

The plasma concentration of repaglinide is reported to increase greatly when given after repeated oral administration of itraconazole and gemfibrozil. The present study analyzed this interaction based...

 Synonyms

(S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid
(S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid
(S)-2-ethoxy-4-(2-(3-methyl-1-(2-(piperidin-1-yl)phenyl)butylamino)-2-oxoethyl)benzoic acid
Repaglinid
2-Ethoxy-4-[2-[[(1S)-3-Methyl-1-[2-(1-Piperidinyl)Phenyl]Butyl]Amino]-2-Oxoethyl]Benzoic Acid
AG EE-623 ZW
(+)-2-Ethoxy-a-[[(S)-a-isobutyl-o-piperidinobenzyl]carbamoyl]-p-toluic acid
MFCD00906179
2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid
Prandin,GlucoNorm,NovoNorm
2-Ethoxy-4-[2-({(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid
Benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-
(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid
Repaglinide
2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid
Top Suppliers:I want be here






Get all suppliers and price by the below link:

Repaglinide suppliers


Price: $73/10mM*1mLinDMSO

Reference only. check more Repaglinide price